What did @averyfisk_ actually say?
The creator laid out an 8-week testosterone cycle timeline, arguing that weeks one and two will produce "absolutely nothing," that strength and recovery gains kick in around weeks three to four, and that weeks five through eight are when users "feel on cycle" with strength jumping "every single session." They also recommended running testosterone alone on a first cycle to isolate how you respond to that compound before adding anything else.
This is anabolic steroid use advice, full stop. The hashtag "gear" is bodybuilding slang for performance-enhancing drugs, and the framing here is not TRT for diagnosed hypogonadism. It is supraphysiological dosing guidance aimed at recreational users seeking muscle and strength gains. That context matters enormously when evaluating the claims.
Does the science back this up?
The broad timeline is roughly consistent with what pharmacokinetic data and clinical studies show, but it flattens a lot of important nuance. The claim that weeks one and two produce "absolutely nothing" is partially wrong.
Testosterone enanthate and cypionate, the most common injectable esters used in bodybuilding cycles, reach near-steady-state serum levels within one to two weeks of the first injection, depending on dose and individual clearance rates (Bhasin et al., 2001, New England Journal of Medicine). Androgen receptor binding and downstream anabolic signaling begin well before subjective strength changes are noticeable. What the creator is describing is the lag between biochemical activation and perceptible performance change, which is real, but it is not the same as "nothing happening."
The weeks three to four strength window aligns with research showing measurable increases in muscle protein synthesis and nitrogen retention within that window at supraphysiological doses (Ferrando et al., 1998, American Journal of Physiology). The weeks five to eight peak experience is consistent with studies on fat-free mass accrual peaking between weeks four and twelve depending on dose (Bhasin et al., 1996, NEJM). The fat loss claim is more complicated and addressed below.
What did they get wrong (or right)?
The creator deserves credit for the single-compound recommendation. Isolating testosterone on a first cycle is genuinely sound harm-reduction logic. If you develop side effects, you know what caused them. That is not controversial, and it is the same advice harm-reduction organizations like the Zack Homol community and even some sports medicine researchers have echoed.
The fat loss claim is where things get shaky. The creator says users "should have some fat loss" by weeks five to eight due to "increased metabolism." This overstates the evidence. Supraphysiological testosterone does increase resting metabolic rate modestly and improves nutrient partitioning, but fat loss during a first cycle is highly dependent on caloric intake. Bhasin et al. (1996) showed fat-free mass gains without significant fat loss in subjects not restricting calories. Presenting fat loss as an expected outcome misleads users about what the compound actually does versus what diet and training do.
The "absolutely nothing" framing in weeks one and two is also worth pushing back on. Androgenic effects, including increased libido, aggression, and early water retention from aromatization to estrogen, often appear within the first week at typical cycle doses. Telling people to expect nothing may cause them to dismiss early side effects as irrelevant.
What should you actually know?
If you are on legitimate, physician-supervised TRT for diagnosed hypogonadism, the timeline the creator describes is directionally relevant but still not your roadmap. Therapeutic dosing is designed to restore physiological levels, not exceed them, so the magnitude of effects described here is not what most TRT patients will experience.
If you are considering a supraphysiological cycle based on TikTok advice, there are things this video does not cover at all. Endogenous testosterone suppression begins within days of starting exogenous testosterone (Bhasin et al., 2001). Cardiovascular risk, including left ventricular hypertrophy and adverse lipid changes, has been documented in long-term anabolic steroid users (Baggish et al., 2017, Circulation). Post-cycle therapy and the timeline for hypothalamic-pituitary-gonadal axis recovery are not mentioned here.
The creator is not presenting this as medical advice, and they never claim to be a doctor. But the audience is real, many are young, and an 18,900-view video presenting a cycle timeline as straightforward and predictable carries real-world weight. The omissions here are as consequential as what was said.